189 related articles for article (PubMed ID: 35327440)
21. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
22. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Rare
Eadie LN; Rehn JA; Breen J; Osborn MP; Jessop S; Downes CEJ; Heatley SL; McClure BJ; Yeung DT; Revesz T; Saxon B; White DL
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833191
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Faulk KE; Kairalla JA; Dreyer ZE; Carroll AJ; Heerema NA; Devidas M; Carroll WL; Raetz EA; Loh ML; Hunger SP; Borowitz M; Wang C; Guest E; Brown PA
Pediatr Blood Cancer; 2023 May; ():e30467. PubMed ID: 37259259
[TBL] [Abstract][Full Text] [Related]
25. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
Leukemia; 2021 May; 35(5):1279-1290. PubMed ID: 33623141
[TBL] [Abstract][Full Text] [Related]
26. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
[TBL] [Abstract][Full Text] [Related]
27. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract][Full Text] [Related]
28. Recurrent
Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
[TBL] [Abstract][Full Text] [Related]
30. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
[TBL] [Abstract][Full Text] [Related]
31. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract][Full Text] [Related]
32. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
33. High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Oikonomou A; Valsecchi L; Quadri M; Watrin T; Scharov K; Procopio S; Tu JW; Vogt M; Savino AM; Silvestri D; Valsecchi MG; Biondi A; Borkhardt A; Bhatia S; Cazzaniga G; Fazio G; Bardini M; Palmi C
Biochem Pharmacol; 2023 Nov; 217():115809. PubMed ID: 37717691
[TBL] [Abstract][Full Text] [Related]
34. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
35. Haploidentical peripheral blood stem cell transplantation without irradiation or busulfan after reduced-intensity conditioning for KMT2A(MLL)-rearranged infant B-cell precursor acute lymphoblastic leukemia: Report of two cases.
Yoshimi A; Kato K; Hosaka S; Suzuki R; Fukushima H; Nakao T; Kobayashi C; Fukushima T; Koike K; Sumazaki R; Tsuchida M
Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28332262
[TBL] [Abstract][Full Text] [Related]
36. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
37. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
Nanya M; Sato M; Tanimoto K; Tozuka M; Mizutani S; Takagi M
PLoS One; 2015; 10(12):e0144540. PubMed ID: 26657054
[TBL] [Abstract][Full Text] [Related]
39. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
40. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
